Analysts Offer Insights on Healthcare Companies: Advaxis (NASDAQ: ADXS) and Aerpio Pharmaceuticals Inc (NASDAQ: ARPO)

By Jason Carr

Analysts fell to the sidelines weighing in on Advaxis (ADXSResearch Report) and Aerpio Pharmaceuticals Inc (ARPOResearch Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.

Advaxis (ADXS)

In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Hold rating on Advaxis, with a price target of $4.30. The company’s shares closed yesterday at $2.57, close to its 52-week low of $2.36.

Ramakanth commented:

“We maintain our Neutral rating of ADXS and our 12-month price target of $4.30 per share. We derive our price target based on the average of two valuation methods: (1) price-sales multiple (6x 2026 sales estimate at 20% discount); and (2) price-earnings multiple (19x 2026 earnings estimate at 20% discount).”

According to TipRanks.com, Ramakanth has 0 stars on 0-5 star ranking scale with an average return of -12.0% and a 30.3% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Gritstone Oncology Inc.

The word on The Street in general, suggests a Hold analyst consensus rating for Advaxis with a $5.15 average price target.

See today’s analyst top recommended stocks >>

Aerpio Pharmaceuticals Inc (ARPO)

H.C. Wainwright analyst Yi Chen initiated coverage with a Hold rating on Aerpio Pharmaceuticals Inc today. The company’s shares closed yesterday at $0.99, close to its 52-week low of $0.88.

Chen observed:

“Our price target is derived from an estimated market value of the firm at $42M, which includes a discounted cash flow- based asset value for AKB-9778 in glaucoma and AKB-4924 (GB004) in inflammatory bowel disease (IBS), using a 15% discount rate and 2% terminal growth rate, and probabilities of success at 20% and 10%,.”

According to TipRanks.com, Chen has 0 stars on 0-5 star ranking scale with an average return of -26.0% and a 31.6% success rate. Chen covers the Healthcare sector, focusing on stocks such as Aslan Pharmaceuticals Ltd, Seelos Therapeutics Inc, and T2 Biosystems.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aerpio Pharmaceuticals Inc with a $8 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.